F10 and stroke disorder: Factor Xa inhibitors, rivaroxaban, apixaban, and edoxaban, have demonstrated non‐inferiority or superiority to warfarin in the prevention of stroke and systemic embolism in randomized clinical trials (RCTs) [4, 5, 6].